Co-promotion of sales and medical affairs percentage.

No definition available.

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Development Milestone Payments Earned To Date Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	mdvn_DevelopmentMilestonePaymentsEarnedToDateUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum dollar amount of milestone payments eligible to be received under a collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments Earned To Date Under Collaboration Agreement.

+ References

No definition available.

+ Details

Name:	mdvn_MilestonePaymentsEarnedToDateUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of all Sublicensing Income, as defined in agreement, payable to licensor.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSublicensingIncome
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Remaining development milestone payments that are eligible to be received in the future under collaboration arrangements.

+ References

No definition available.

+ Details

Name:	mdvn_RemainingFutureDevelopmentMilestonePaymentsEligibleToReceiveUnderCollaborationArrangements
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Remaining sales milestone payments that are eligible to be received in the future under collaboration arrangements.

+ References

No definition available.

+ Details

Name:	mdvn_RemainingFutureSalesMilestonePaymentsEligibleToReceiveUnderCollaborationArrangements
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalties at percentage rates ranging.

+ References

No definition available.

+ Details

Name:	mdvn_RoyaltiesAtPercentageRatesRanging
Namespace Prefix:	mdvn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014 Collaborative agreement [Member]	Jun. 30, 2014 Scenario, Forecast [Member]	Mar. 31, 2014 Astellas Pharma Inc. [Member] Collaborative agreement [Member]	Dec. 31, 2009 Up-front cash payment arrangement [Member] Astellas Pharma Inc. [Member]	Mar. 31, 2014 Development milestone payments [Member] Astellas Pharma Inc. [Member]	Jun. 30, 2014 Development milestone payments [Member] Astellas Pharma Inc. [Member] Scenario, Forecast [Member]	Mar. 31, 2014 Sales milestone payments [Member] Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion of sales and medical affairs percentage		50.00%
Royalty received on ex-U.S. sales per collaboration arrangement				Low teens to the low twenties
Non-refundable, up-front cash payment					$ 110.0
Eligible to receive milestone payments						335.0		320.0
Milestone payments earned						93.0		25.0
Remaining future sales milestone payments the Company is eligible to receive								295.0
Remaining future development milestone payments the Company is eligible to receive						242.0
Collaboration revenue	$ 78.0		$ 7.0				$ 47.0
Percentage of Sublicensing Income						10.00%